West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the America…
$399.81+1.87%
报价 2026-11-06
市值
$27.85B
EV
$28.25B
PE (TTM)
45.5x
预期 PE (FY2026)
42.3x
52 周区间距高点 -4.0%
$230.95$416.67
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 9.20 → 10.34（1.1x） | 38.7 |
| FY+32028-12 | 1.2x | 9.20 → 11.88（1.3x） | 33.6 |
毛利率 38% · TTM 收入 $3397M · 基数 EPS 9.20（调整后）
电话会信号
辅助标签Q3 20262026-10-29
扩产需求加速上调指引
指引 上调
信心 4
分析师 4
“We expect full year operating margins to expand almost 300 basis points, above our long-term growth construct.”
原文引用（3）
- 扩产：kicking off a new wave of meaningful capital investments to expand our HVP finishing capacity, both in Europe and the U.S.
- 需求加速：Our GLP-1 HVP business also performed very well, accelerating nicely in the quarter
- 上调指引：we now anticipate full year revenue to be in the range of $3.41 billion-$3.42 billion, up from a prior range of $3.345 billion-$3.38 billion
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| WSTWest Pharmaceutical Services, Inc. | $27.85B | +1.9% | +11.6% | 39.7% | 45.5x | 29.2x | 62.7x | |
| WATWaters Corporation | $44.93B | +1.0% | +103.6% | 58.9% | 28.0x | 18.3x | 83.3x | 高增长 |
| ILMNIllumina, Inc. | $32.23B | +2.5% | +7.6% | 66.4% | 49.5x | 30.8x | 43.1x | |
| LHLabcorp Holdings Inc. | $29.77B | +0.9% | +5.9% | 29.8% | 27.6x | 15.9x | 23.9x | |
| DGXQuest Diagnostics Incorporated | $28.21B | +0.3% | +10.0% | 33.7% | 24.3x | 15.6x | 21.0x | GARP |
| STESTERIS plc | $24.6B | -0.7% | +7.3% | 44.7% | 29.9x | 17.0x | 26.3x | |
| INCYIncyte Corporation | $24.39B | +1.4% | +12.9% | 91.8% | 13.9x | 8.5x | 17.9x | |
| ZBHZimmer Biomet Holdings, Inc. | $20.14B | -1.2% | +4.7% | 71.2% | 26.6x | 11.9x | 12.2x | |
| MEDPMedpace Holdings, Inc. | $18.27B | +2.9% | +13.5% | 31.3% | 36.9x | 28.6x | 28.4x | |
| 同行中位数 | – | – | +8.8% | 51.8% | 27.8x | 16.4x | 25.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $874.5M | $872.3M | $844.9M | $805M | $804.3M | $766.2M | $698.2M | $748.5M |
| Gross Margin | 39.7% | 37.7% | 35.1% | 37.8% | 36.5% | 35.7% | 33.3% | 36.7% |
| Operating Margin | 30.6% | 20.5% | 21% | 19.5% | 21.6% | 20.6% | 18.4% | 22.8% |
| Net Income | $214M | $154M | $138.8M | $132.1M | $140M | $131.8M | $89.8M | $130.1M |
| Diluted EPS | 3.02 | 2.15 | 1.92 | 1.82 | 1.93 | 1.82 | 1.23 | 1.78 |
| Operating Cash Flow | $189.5M | $124M | $89.9M | $251.1M | $197.2M | $177.1M | $129.4M | $190.1M |
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。